{
  "folder": "IC-124",
  "content": "{{knowledge objective\n|Identifiant=OIC-124-12-B\n|Item_parent=Menopause, premature ovarian failure, andropause, age-related androgen deficiency (See item 330)\n|Item_parent_short=Menopause, premature ovarian failure, andropause, age-related androgen deficiency (See item 330)\n|Rank=B\n|Title=Knowing the benefit-risk balance of HRT in the case of natural menopause and premature ovarian failure and the alternatives to HRT.\n|Description=None\n|Rubric=Management\n|Contributors=Florence Tr\u00e9mollieres,Anna Gosset\n|Order=12}}\n\n== '''Balance of benefits and risks of HRT in natural menopause''' ==\n{| class=\"wikitable\"\n|\n!'''Benefits'''\n!'''Risks'''\n|-\n|'''Climacteric syndrome''''\n|The most effective treatment for the functional signs of the menopause\n|\n|-\n|Fracture risk\n|1st-line treatment to prevent postmenopausal bone loss\n|\n|-\n|'''Cardiovascular impact''''\n|\u2193Risk of MI if HRT is started within 10 years of the menopause.\n\n\u2192Risk of stroke and neutral VTE with cutaneous route+ progesterone or dydrogesterone.\n|\u2191 risk of MI if HRT is started > 10 years after menopause\n|-\n|'''Carcinological risk''''\n|\u2193 Risk of colorectal cancer\n\n\u2193Overall mortality\n|\u2191 risk of breast cancer ''(absence of excess risk in European observational studies for a duration of 5-7 years)''\n\n\u2191 risk of endometrial cancer ''(annihilated by taking a progestin at least 12 days a month)''\n\n\u2191 risk of ovarian cancer ''(RR=1.14[1.10-1.19])''\n|}\n\n'''Overall, the benefit/risk balance of HRT is still considered positive in women who are symptomatic and/or at risk of osteoporosis in the first 10 years of the menopause or before the age of 60'''.\n\n== Balance of benefits and risks of HRT for premature ovarian failure (PFO) ==\nIn the case of POI, the term ''hormone replacement therapy'' (HRT) is used.\n\nIn the absence of HRT in women with POI, there is an increase in\n\n* cardiovascular mortality\n* osteoporosis\n* cognitive degeneration\n\nContinuation of HRT recommended until the theoretical age of physiological menopause (no increased risk of breast cancer compared with a woman who is still regulated).\n\n'''All in all, the benefit/risk balance of HRT is always positive in cases of POI, cancelling out the cardiovascular and bone risks induced by early oestrogen deficiency''''.\n<br />\n\n== Alternatives to HRT ==\nNon-hormonal alternatives for the treatment of flushing are less effective than HRT\n\nSeveral alternatives are available\n\n=== Pharmacological alternatives ===\nCertain treatments with a main effect and a marketing authorisation (MA) that is not the management of the functional signs of the menopause have a demonstrated positive effect on the frequency and severity of BVMs.\n\n* serotonin reuptake inhibitors\n* clonidine\n* gabapentin\n\n=== Food supplements, phytoestrogens, pollen extracts, phytotherapy ===\nIn general, no proven efficacy compared to placebo\n\nBe careful with phytoestrogens, which are contraindicated if you have a history of breast cancer.\n\n=== Non-pharmacological alternatives ===\nThere is some evidence that acupuncture, yoga and hypnosis can reduce the frequency and intensity of BVMs.",
  "question": {
    "question": "What is the recommended duration of HRT for women with premature ovarian failure (PFO) to balance benefits and risks?",
    "option_a": "Until the age of 50",
    "option_b": "Until the theoretical age of physiological menopause",
    "option_c": "No specific duration, as HRT is not recommended for PFO",
    "option_d": "10 years after the onset of PFO",
    "correct_option": "B"
  }
}